Nothing said here yet.
to join the conversation.
| HEALY JAMESDirector | Buy | 952,380 | $20.0M | Wed, Oct 28 |
| HEALY JAMESDirector | Buy | 6,933 | $145.6K | Wed, Oct 28 |
| HEALY JAMESDirector | Buy | 6,395 | $134.3K | Wed, Oct 28 |
| HEALY JAMESDirector | Buy | 3,772 | $79.2K | Wed, Oct 28 |
| Sanchez RamiroDirector | Buy | 3,600 | $98.5K | Fri, Oct 23 |
| PAUL STEVEN MDirector | Buy | 35,714 | $974.3K | Thu, Oct 22 |
| MARAGANORE JOHNDirector | Buy | 8,239 | $217.3K | Thu, Oct 22 |
| Young Wendy B.Director | Buy | 3,789 | $100.0K | Thu, Oct 22 |
| Silva Paul MDirector | Buy | 3,680 | $99.6K | Thu, Oct 22 |
| MARAGANORE JOHNDirector | Buy | 1,172 | $31.5K | Thu, Oct 22 |
| Ignelzi Troy A.Chief Financial Officer | Buy | 5,500 | $143.6K | Wed, Oct 21 |
| Ceesay AbrahamChief Executive Officer | Sell | 2,210 | $64.4K | Wed, Oct 21 |
Rapport Therapeutics (RAPP) said Wednesday it priced separate offerings of $175 million of common s
Investing.com -- Rapport Therapeutics Inc (NASDAQ:RAPP) shares fell 20% in premarket trading Wednesday following the pricing of $350 million in combined stock and convertible note offerings.
Key TakeawaysRapport Therapeutics shares fell 22% today after it priced about $380 million of stock, pre-funded warrants, convertible notes and a private placement, with the shares sold at $21 each.
Rapport Therapeutics (NASDAQ:RAPP) reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and supporting plans to advance the candidate into…
New Executive Hires Strengthen Leadership Team as Patrick Ta Beauty Enters Its Next Chapter LOS ANGELES, Oct.
Rapport Therapeutics (RAPP) moved into focus after reporting that lead candidate RAP-219 met its primary endpoint in a Phase 2 trial for acute bipolar I mania, with statistically significant efficacy and a favorable tolerability profile.
The latest valuation work on Rapport Therapeutics lifts estimated fair value from US$62.88 to US$69.06, putting a sharper focus on how RAP-219 could shape the long term story.